KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Authors
Shitara, KÖzgüroğlu, M
Bang, Y
Di Bartolomeo, M
Mandalà, M
Ryu, M
Fornaro, L
Olesiński, T
Caglevic, C
Chung, H
Muro, K
Gökkurt, E
Mansoor, Was
McDermott, R
Schacham-Shmueli, E
Chen, X
Kang, S
Mayo, C
Ohtsu, A
Fuchs, C
Affiliation
National Cancer Center Hospital East, Kashiwa, JapanIssue Date
2018-06
Metadata
Show full item recordCitation
KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. 2018, 29(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdy208.004Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy208.004